论文部分内容阅读
目的观察化疗和化学-内分泌治疗对术后复发或转移的进展期胃癌患者的临床疗效。方法将54例进展期胃癌患者(均有病理证实和客观体征)随机分为EAP(足叶乙甙十阿霉素+顺铂)和EAP -TAM(三苯氧胺)两组进行治疗,同时测定雌激素受体的状态。结果对雌激素受体阳性患者EAP -TAM治疗组有效率为73.3%,而EAP治疗组仅为50.0%,两组之间有明显的统计学差异(P<0.05);对雌激素受体阴性患者,两组有效率分别为50.0%和52.9%,无统计学差异(P>0.05)。在雌激素受体阳性患者中,EAP -TAM治疗的有效率与雌激素受体的含量呈正比关系。本组试验中没有观察到三苯氧胺的毒副作用。结论内分泌治疗对雌激素受体阳性的胃癌患者有着明显的疗效,而对雌激素受体阴性的胃癌患者无效。
Objective To observe the clinical effects of chemotherapy and chemoembolization on advanced gastric cancer patients with recurrent or metastatic disease. Methods 54 patients with advanced gastric cancer (both pathologically confirmed and objective signs) were randomly divided into EAP (Etoposide and doxorubicin + cisplatin) and EAP-TAM (tamoxifen) two groups for treatment, while estrogen Receptor status. Results The effective rate of EAP-TAM-treated patients was 73.3%, while that of EAP-treated patients was only 50.0%. There was a significant difference between the two groups (P <0.05). The positive rate of estrogen receptor-negative Patients, the two groups were 50.0% and 52.9%, respectively, with no significant difference (P> 0.05). In estrogen receptor positive patients, EAP-TAM treatment efficiency and estrogen receptor content was directly proportional relationship. No adverse effects of tamoxifen were observed in this group of trials. Conclusion Endocrine therapy has obvious curative effect on estrogen receptor positive gastric cancer patients, but not on estrogen receptor negative gastric cancer patients.